SCIENCE / NMN + RESVERATROLTWO INGREDIENTS · ONE IMPORTANT DISTINCTION
NMN has shown a promising muscle-metabolism signal. Resveratrol has shown small benefits in selected metabolic and cognitive tests. Together, they make an interesting research question, not yet a proven better combination.
See the measured resultsOral ingredient research. Not proof of longer life or results from a finished Neurogan product.
01 / WHAT WAS ACTUALLY TESTED
Two ingredients can be biologically related without being clinically proven to work better together.
NMN is used to make NAD+, a molecule involved in energy metabolism and other cell processes. Some trials show changed blood measurements and selected physiological signals.
Blood NAD is not a measurement of lifespan, energy felt throughout the day or NAD in every tissue. [1] [2]
Resveratrol is studied for effects on cell signaling and circulation. Human findings vary with the population, dose, preparation and outcome being measured.
A favorable laboratory mechanism does not guarantee a benefit when swallowed. [4] [5]
This focused search did not identify a published controlled trial testing oral NMN plus resveratrol together in people.
This is a search finding, not proof that no unpublished or unindexed study exists. No finished Neurogan combination trial was identified.
Searches used NMN and its full name, nicotinamide mononucleotide, with resveratrol, human, oral, combination and randomized clinical trial. Primary journal and PubMed records were checked, alongside relevant ClinicalTrials.gov results. This is a selected evidence guide, not a registered systematic review or an exhaustive trial-registry search. Sources and English product listings checked September 9, 2026.
A common mix-up: the NICE trial tested nicotinamide riboside (NR), with and without resveratrol, in 90 people with peripheral artery disease over six months. NR is not NMN. That study cannot be presented as an NMN + resveratrol trial. [9]
To establish whether the pair is better, a trial would need NMN alone, resveratrol alone, both together and a control, with comparable doses and prespecified outcomes. Animal and cell studies cannot substitute for that comparison.
02 / MEASURED RESULTS
These visuals keep the tested ingredient and comparator visible. They are not a combined-benefit score.
In women with prediabetes, muscle used glucose more effectively during a controlled insulin-infusion test after NMN. This was a specific muscle result, not a general improvement in blood sugar.
250 mg/day · 10 weeks · 13 NMN, 12 placebo · Yoshino et al. [1]
CHANGE FROM THE NMN GROUP’S OWN BASELINE
Muscle insulin sensitivity
Reported change: 25 ± 7% (mean ± SEM)
In 11 men with obesity, a fasting-blood-test index was lower after resveratrol than after placebo. Each man completed both treatment periods.
150 mg/day resVida · 30 days per period · Timmers et al. [4]
HOMA INDEX · LOWER INDICATES LESS INSULIN RESISTANCE
Difference in period means: −0.37 index units
A larger trial offers an important check on expectations: pain eased to a similar degree with resveratrol and placebo added to usual care.
142 adults with knee osteoarthritis · primary endpoint at 3 months · Nguyen et al. [7]
REDUCTION IN PAIN · POINTS ON A 0–100 SCALE
Reported between-group difference: −0.6 points
95% CI −8.0 to 6.9 · p = 0.88
03 / READ THE HUMAN STUDIES
Dose, population and method change what a result can tell us. Open each study for more detail.
NMN ONLY · Yoshino et al. · Science · 2021
What happened: Muscle insulin sensitivity increased 25 ± 7% relative to the NMN group’s baseline; placebo showed no significant change. [1]
The boundary: This was not improved insulin sensitivity in every organ, weight loss or diabetes prevention.
Who and what: 13 women received NMN supplied by Oriental Yeast; 12 received placebo. The study used swallowed NMN, without resveratrol.
Method: a hyperinsulinemic-euglycemic clamp with tracers assessed glucose handling during controlled insulin exposure. Muscle biopsies assessed signaling and NAD-related biology. Blood-cell NAD+ rose, but steady-state muscle NAD+ did not.
Results: insulin-stimulated glucose disposal per kg fat-free mass rose after NMN (within-group p < 0.01); the three-way interaction was p = 0.022. Muscle insulin-signaling proteins responded. Liver and adipose-tissue insulin sensitivity, fasting metabolic measures, body composition and physical performance did not improve.
Limits and safety: a small, selected female population and short exposure. No adverse events or standard-blood-test abnormalities were reported, which does not establish long-term safety. The paper reports commercial relationships and NMN-related intellectual-property interests among authors.
NMN ONLY · Yi et al. · GeroScience · 2023, online 2022
What happened: Serum total NAD (NAD+ plus NADH) increased and six-minute walking outcomes favored NMN. [2]
The boundary: HOMA-IR did not show a significant benefit. Serum total NAD is not the same as NAD+ in whole blood, muscle or brain.
Design: 20 participants per group received placebo or one of three NMN doses. AbinoNutra NMN was supplied in 150 mg capsules; no resveratrol was given. Measurements were taken at baseline, day 30 and day 60.
Outcomes: serum total NAD, measured with a colorimetric assay, was the primary endpoint. Walking performance and other health measures were secondary. A calculator-derived biological-age value stayed unchanged with NMN while increasing with placebo; this was not demonstrated reversal of aging.
Limits: small groups, many secondary endpoints and ingredient-company sponsorship. Different blood compartments and assays cannot be placed on a single NAD-boost scale. No NMN-related adverse events were reported over 60 days; effects over years remain uncertain.
NMN ONLY · POOLED EVIDENCE · Chen et al. · Current Diabetes Reports · online 2024
What happened: No significant pooled benefit on fasting glucose, fasting insulin, HbA1c, HOMA-IR or lipid profile. [3]
The boundary: These routine metabolic outcomes differ from the muscle clamp endpoint. A null pooled result is not proof that every possible NMN effect is absent.
Evidence base: trials published in 2021–2023, mainly relatively healthy, non-diabetic middle-aged or older adults. Doses and populations varied, and each endpoint used the trials reporting it.
Interpretation: the review does not confirm broad improvements in glucose or cholesterol control. Its trial participants overlap individual studies summarized here and must not be counted as additional independent participants.
Access and limits: primary review abstract verified. It does not supply numerical pooled estimates or confidence intervals, so pooled benefit sizes are not charted here. Small trials and brief follow-up limit conclusions for people with established disease or long-term use.
RESVERATROL ONLY · Timmers et al. · Cell Metabolism · 2011
What happened: The HOMA index was 2.80 ± 0.20 after placebo and 2.43 ± 0.24 after resveratrol (mean ± SEM, p = 0.03). Several other metabolic markers also favored resveratrol. [4]
The boundary: HOMA is an estimate from fasting blood tests, not the clamp test used in the NMN study. These outcomes cannot be added together.
Design and dose: each participant received 150 mg/day of 99% resveratrol (resVida) and placebo in separate 30-day periods, with a four-week washout. DSM Nutritional Products provided the ingredient.
Table 2 results: glucose was 5.28 ± 0.15 versus 5.06 ± 0.13 mmol/L (placebo versus resveratrol, p = 0.05); insulin was 11.94 ± 1.11 versus 10.31 ± 1.25 mU/L (p = 0.04). The HOMA difference was −0.37 index units. Values are endpoint means ± SEM, not individual starting values.
Other findings: selected blood-pressure, liver-fat and mitochondrial measures improved. Body mass did not. Eleven men, numerous measurements and one month per treatment make this an exploratory study, not a reliable prediction for a retail blend or longer life.
RESVERATROL ONLY · NULL · Poulsen et al. · Diabetes · 2013
What happened: The primary insulin-sensitivity outcome did not significantly improve. Neither did HOMA-IR, fasting glucose or fasting insulin. [5]
The boundary: More milligrams did not mean a better result in this experiment. Different designs and populations prevent a simple dose ranking.
Method and exposure: 26 men enrolled and 24 were analyzed, 12 per arm. Participants took 500 mg trans-resveratrol three times daily or placebo for four weeks. One participant withdrew because of MRI claustrophobia; another was excluded after a generalized rash. Insulin sensitivity was assessed with a hyperinsulinemic-euglycemic clamp, a controlled physiological test rather than a fasting-blood estimate.
Results: the primary clamp endpoint was null. Body composition and the broader metabolic evaluation did not support the favorable general metabolic picture of the earlier pilot.
Limits: only 24 men and brief treatment. A null result at 1,500 mg/day does not prove all other doses are ineffective, but it does challenge the idea that increasing the dose reliably improves metabolism. No NMN was administered.
RESVERATROL ONLY · Thaung Zaw et al. · Clinical Nutrition · 2021, online 2020
What happened: Overall cognitive performance favored resveratrol, with a small standardized effect (Cohen’s d = 0.170; p = 0.005). Cerebrovascular measures also improved. [6]
The boundary: This is a small test-score effect, not demonstrated dementia prevention, a percentage increase in intelligence or evidence for the combination.
Design: a 24-month study with 12 months of resveratrol and 12 months of placebo, switching treatments. It was not 24 continuous months of active supplementation. Cognition was the primary outcome; cerebrovascular and cardiometabolic outcomes were secondary.
Results: resting cerebral blood-flow velocity had d = 0.275 (p = 0.001); responsiveness to carbon dioxide had d = 0.307 (p = 0.027). These are standardized effects, not percent changes in brain blood flow or memory.
Limits: the primary abstract reports a relative cognitive percentage without explaining its denominator. The small standardized effect is therefore more interpretable here. Absolute cognitive-score changes, detailed attrition and washout information were not verified from full text. Related reports from RESHAW describe the same trial, not independent replications. Dementia incidence was not established as improved.
RESVERATROL ONLY · NULL · Nguyen et al. · PLOS Medicine · 2024
What happened: At three months, pain changed by −15.7 points with resveratrol and −15.2 with placebo. The reported difference was −0.6 points (95% CI −8.0 to 6.9; p = 0.88). [7]
The boundary: Both groups continued usual care. Improvement from baseline does not establish that resveratrol caused the improvement.
Dose and preparation: 40 mg twice daily for the first week, then 20 mg twice daily for the remainder of six months. This was a patented soluble preparation supplied by Yvery, not a generic micronized retail capsule and not a blend with NMN.
Method: three French tertiary centers randomized 71 people per arm. Mean age was 61.4 years. The primary outcome was change in knee pain at three months on a 0–100 numeric rating scale. Mean baseline pain was 56.2/100 overall.
Results: no superiority on primary pain reduction. The 95% confidence interval spans benefit and harm; this does not establish precise equivalence. The resveratrol change CI was −21.1 to −10.3; placebo was −20.5 to −9.8.
Limits: recruitment stopped below target; 120 of 142 completed the allocated intervention. Seven primary-outcome values were missing. Adherence and background care affect interpretation. Better absorption, by itself, did not ensure a positive clinical result.
RESVERATROL + EXERCISE · NO NMN · Gliemann et al. · Journal of Physiology · 2013
What happened: The increase in maximal oxygen uptake was smaller with resveratrol than with placebo. Several other training endpoints were mixed. [8]
The boundary: This is a caution about selected training adaptations, not proof that resveratrol cancels exercise or harms all users.
Design: 14 men received resveratrol and 13 placebo, both with exercise training. Mean age was about 65. No NMN was given.
Results: the primary abstract reports a greater increase in maximal oxygen uptake in the placebo group. It also reports blood-pressure and lipid findings favoring placebo in selected analyses, while other outcomes were unaffected.
Interpretation matters: subsequent commentary challenged broad “abolished benefit” language and noted that a significant within-group change in one arm but not another is not automatically a significant between-group difference. Many outcomes were similar. This small study does not support a universal performance benefit or a blanket claim of harm. [11]
04 / FROM A TRIAL TO A LABEL
Current Neurogan Health combination listings were checked directly, including the Supplement Facts images. Product amounts are label comparisons, not dose recommendations.
None of these selected trials tested the current Neurogan NMN + resveratrol formula.
A smaller-particle ingredient is not automatically clinically superior. The selected studies do not establish a retail absorption or benefit advantage.
The NMN blend listing states a two-capsule serving but suggests one capsule daily. Those are different amounts.
| Current listing | Supplement Facts | Directions and study relevance |
|---|---|---|
| NMN + Resveratrol Capsules ↗ | Two capsules: 600 mg beta-NMN + 600 mg micronized trans-resveratrol. 90 capsules per bottle. View Supplement Facts ↗ | The page suggests one capsule daily. Calculated from the label, that is 300 mg NMN + 300 mg resveratrol, not 1,200 mg of each or 1,200 mg per capsule. Confirm directions with the bottle/manufacturer. Neither this pair nor its 1:1 ratio has established clinical superiority. |
| NAD + Resveratrol Capsules ↗ DIFFERENT MOLECULE | Two capsules: 600 mg nicotinamide adenine dinucleotide + 600 mg micronized trans-resveratrol. 90 capsules; 45 servings. View Supplement Facts ↗ | The page suggests two capsules daily. NAD+ is not NMN or NR. NMN-only trials cannot substantiate the NAD+ component of this product. The similar combined milligram total does not make the formulas interchangeable. |
Labels and page directions can change. The current English listing and its label image are used here rather than older blog or translated descriptions. Potency testing checks composition; it does not demonstrate clinical benefit.
The NMN blend’s labeled two-capsule serving provides 600 mg of each ingredient. Its NMN amount overlaps an arm in the 60-day NMN-only trial, but matching one ingredient’s milligrams does not match that trial’s preparation or add-on resveratrol exposure. The positive resveratrol metabolic and cognitive trials used 150 mg/day, not 600 mg/day.
The 250 mg/day NMN muscle study and 150 mg/day resveratrol studies were conducted in different people with different tests. Taking both does not recreate either trial. No optimal NMN-to-resveratrol ratio or long-term combination dose was established in the selected evidence.
05 / SAFETY & LIMITATIONS
The combination needs its own safety evidence. Separate short-term tolerability results are not a guarantee for years of combined use.
Resveratrol may increase bleeding risk with anticoagulants or antiplatelet medicines. Human studies at 1 gram/day for four weeks found effects on drug-metabolizing enzymes. The size of any interaction at this blend’s dose is not established. [10]
Resveratrol can cause gastrointestinal side effects, especially at higher doses. Selected NMN trials reported acceptable short-term tolerability, but uncommon or delayed harms could be missed. [1] [2] [10]
Safety is not established here for pregnancy, breastfeeding or children. Discuss use with your clinician for cancer treatment, hormone-sensitive conditions, major liver or kidney disease, or planned surgery. [10]
Bring the complete supplement label and medication list. Resveratrol can affect CYP3A4, CYP2D6, CYP2C9 and CYP1A2, enzymes used to process many medicines. The human enzyme study cited by Memorial Sloan Kettering used 1 gram daily for four weeks; it does not quantify the effect of this retail blend.
Anticoagulants such as warfarin, antiplatelet medicines, and medicines with narrow therapeutic ranges merit particular review. Potential bleeding effects are not a quantified clinical risk estimate for this product. Resveratrol also has estrogen-like activity, which is relevant to hormone-sensitive conditions. Do not change prescribed treatment to accommodate a supplement. [10]
No human lifespan extension, reversal of aging, disease prevention, dependable weight loss, universal memory benefit or proven NMN + resveratrol synergy is established by these studies. A changed biomarker may be scientifically informative without changing long-term health.
Many trials are small, short or narrowly selected. Some are industry-supported. Multiple endpoints create more opportunities for chance-positive findings. A p-value does not describe benefit size; a confidence interval describes uncertainty under the study’s statistical assumptions.
This is a focused selection of informative positive and null studies, not every published trial. Combination search results can change with new publications. The main reason to remain cautious is missing direct evidence, not proof that the pair is ineffective.
THE TAKEAWAY
The most credible story is not that two supplements must work better than one. It is that each has human findings worth understanding, and the pair still needs direct testing.
Follow the evidence ↓06 / SOURCES & FURTHER READING
Primary publications and the pooled review are distinguished below. Product listings are cited separately above. Multiple papers from one trial are not counted as independent replications.
Yoshino et al. · Science · 2021
Read source 1 ↗Yi et al. · GeroScience · 2023, online 2022
Read source 2 ↗Chen et al. · Current Diabetes Reports · online 2024
Read source 3 ↗Timmers et al. · Cell Metabolism · 2011
Read source 4 ↗Poulsen et al. · Diabetes · 2013
Read source 5 ↗Thaung Zaw et al. · Clinical Nutrition · 2021, online 2020
Read source 6 ↗Nguyen et al. · PLOS Medicine · 2024
Read source 7 ↗Gliemann et al. · Journal of Physiology · 2013
Read source 8 ↗McDermott et al. · Nature Communications · 2024
Read source 9 ↗Memorial Sloan Kettering Cancer Center
Read source 10 ↗Smoliga & Blanchard · Journal of Physiology · 2013
Read source 11 ↗
